Xencor, Inc.

Allergan, Inc.

Genentech, Inc.

Matthew J Bernett

John R Desjarlais

Gregory L Moore

Rumana Rashid

Seung Yup Chu

Umesh Muchhal

Rajat Varma

Christine Bonzon

Gregory Alan Lazar

Sung-Hyung Lee

Michael Hedvat

Alex Nisthal

Sher Bahadur Karki

Holly M Horton

John O Richards

Duc-Hanh Thi Nguyen

Juan Diaz

Eugene Alexander Zhukovsky

Erik Weiking Pong

Nargess Hassanzadeh-Kiabi

Ke Liu

Suzanne Schubbert

Arthur J Chirino

Jonathan Zalevsky

Sergei A Ezhevsky

Darian Cash

Yanbin Liang

Peter C Baciu

Yoon Kyung Kim

Jason Guu

Bassil I Dahiyat

Matthew S Faber

Chad Borchert

Jing Qi

Kendra N Avery

Dilki Wickramarachchi

Dilki Wickramarachichi

Katrina Bykova

Eric Chang

Raphael Clynes

Christine Huang

Patrick Holder

Umesh S Muchhal

In one aspect, the present invention provides heterodimeric antibodies comprising a first monomer comprising a first heavy chain constant domain comprising a first variant Fc domain and a first antigen binding domain and a second monomer comprising a second heavy chain constant domain comprising a second variant Fc domain and a second antigen binding domain. In an additional aspect the heterodimeric antibody comprises a first monomer comprising a heavy chain comprising a first Fc domain and a single chain Fv region (scFv) that binds a first antigen, wherein the scFv comprises a charged scFv linker. The heterodimeric antibody further comprises a second monomer comprising a first heavy chain comprising a second Fc domain and a first variable heavy chain and a first light chain.

Heterodimeric proteins

Provided herein are novel CLDN6 binding domains, and anti-CLDN6×anti-CD3 antibodies that include such CLDN6 binding domains. Also provided herein are methods of using such antibodies for the treatment of CLDN6-associated cancers.

Heterodimeric antibodies that bind CD3 and CLDN6

The present invention provides binding agents comprising at least two binding domains, wherein a first binding domain has specificity for CLDN18.2 and a second binding domain has specificity for CD3, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.

Bispecific binding agents binding to CLDN18.2 and CD3

The present invention is directed to novel heterodimeric antibodies.

Heterodimeric antibodies that bind CD3 and tumor antigens

The present invention is directed to novel IL-15/IL-15Rα heterodimeric Fc fusion proteins and uses thereof. The IL-15/IL-15Rα heterodimeric Fc fusion proteins can be administered to a patient to treat cancer. In some cases, the IL-15/IL-15Rα heterodimeric Fc fusion protein is administered in combination with a checkpoint blockage antibody such as a PD-1 antibody.

IL-15/IL-15RA heterodimeric Fc fusion proteins and uses thereof

The present invention provides novel IL-12 Fc fusion proteins, methods of making and using the same. The IL-12 Fc fusion proteins are useful for treatment of cancer and can be used in combination with checkpoint blockade.

IL-12 heterodimeric Fc-fusion proteins

The present invention is directed to bispecific, heterodimeric checkpoint antibodies.

Bispecific and monospecific antibodies using novel anti-PD-1 sequences

The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc fusion protein and an antigen binding domain Fc fusion proteins. In some instances, the antigen binding domain binds to CD8, NKG2A, or NKG2D.

Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains

The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.

Heterodimeric antibodies that bind CD3 and CD38

The present invention provides untargeted and targeted IL-10-Fc fusion proteins, compositions and methods of use thereof. The targeted IL-10-Fc fusion proteins includes those that bind PD-1, TIGIT, CD8 and NKG2D.

Untargeted and targeted IL-10 Fc-fusion proteins

The present invention provides IL-2-Fc fusion proteins comprising IL-2 variants.

Engineered IL-2 Fc fusion proteins

The present invention relates to fusion proteins comprising variant IL-15 proteins, fusion proteins comprising variant anti-PD-1 antigen binding domains, and fusion proteins comprising variant IL-15 proteins and variant anti-PD-1 antigen binding domains. The present invention also relates to nucleic acid molecules, expression vectors, host cells and methods for making such fusion proteins and the use of such fusion proteins in the treatment of cancer.

PD-1 targeted IL-15/IL-15Rα Fc fusion proteins with improved properties

Provided herein are novel GPC3 binding domains, and antibodies that include such GPC3 binding domains (e.g., anti-GPC3×anti-CD3). Also provided herein are methods of using such antibodies for the treatment of GPC3-associated cancers.

Heterodimeric antibodies that bind CD3 and GPC3

Growing community of inventors

Monrovia, CA, United States of America

Matthew J Bernett